HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Deal Watch: Allergan Keeps After Hair Loss With Exicure Deal

Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.

Deals Business Strategies

‘Watch China’ As Its Pharma Butterfly Flaps Its Wings

More affordable drug prices worldwide could result from China’s ongoing reforms in the life sciences sector, the FT Global Pharmaceutical and Biotechnology Conference hears.

China Commercial

ASLAN Falls As TreeTopp BTC Study Fails

ASLAN’s pivotal Phase II TreeTopp study of varlitinib in biliary tract cancer missed its co-primary endpoints of progression-free survival and overall response rate.

Cancer Clinical Trials

Evotec, Vifor JV To Fight Kidney Disease

Evotec’s CSO says its new joint venture with Vifor will use patient-driven data to identify and develop targeted therapies to treat kidney disease with.

Commercial Companies

Vifor Boosts US Nephrology Prospects With Janssen Pact

Vifor has boosted its US nephrology prospects with a pact with Janssen to jointly market Invokana in diabetic kidney disease.

Deals Companies

GSK Says Shingrix Shortage, Oncology Push Continues

GlaxoSmithKline said its increasingly streamlined operations are on a growth trajectory, but that capacity constraints mean demand for its popular shingles vaccine will keep outstripping supply.

Commercial Companies
See All
UsernamePublicRestriction

Register